

1 **Mucosal Correlates of Protection after Influenza Viral Challenge of Vaccinated and** 2 **Unvaccinated Healthy Volunteers**

3 Rachel Bean,^{a*} Luca T. Giurgea,^{a#} Alison Han,^a Lindsay Czajkowski,^a Adriana Cervantes-
4 Medina,^a Monica Gouzoulis,^a Allyson Mateja,^b Sally Hunsberger,^c Susan Reed,^a Rani Athota,^a
5 Holly Ann Baus,^a John C. Kash,^d Jaekeun Park,^c Jeffery K. Taubenberger,^d Matthew J. Memoli^a

6
7 ^aLID Clinical Studies Unit, Laboratory of Infectious Diseases, National Institute of Allergy and
8 Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA

9 ^bClinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer
10 Research, Frederick, Maryland, USA

11 ^cBiostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National
12 Institutes of Health, Bethesda, Maryland, USA

13 ^dViral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institute
14 of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA

15 ^eDepartment of Veterinary Medicine, VA-MD College of Veterinary Medicine, University of
16 Maryland, College Park, MD

17 Running title: Mucosal Correlates of Protection against Influenza

18 # Address correspondence to Luca T. Giurgea, luca.giurgea@nih.gov

19 *Present address: Rachel Bean, Food and Drug Administration, Silver Spring, Maryland, USA

20 Rachel Bean and Luca T. Giurgea contributed equally to this work. Author order was determined
21 on the basis of chronological contribution to work.

22 Abstract word count: 246

23 Text word count: 4231

24 **Abstract:**

25 Induction of systemic antibody titers against hemagglutinin has long been the main focus of
26 influenza vaccination strategies, but mucosal immunity has also been shown to play a key role in
27 protection against respiratory viruses. By vaccinating and challenging healthy volunteers, we
28 demonstrated that inactivated influenza vaccine (IIV) modestly reduced the rate of influenza
29 while predominantly boosting serum antibody titers against hemagglutinin (HA) and HA stalk, a
30 consequence of the low neuraminidase (NA) content of IIV and the intramuscular route of
31 administration. Not surprisingly, viral challenge induced nasal and serum responses against both
32 HA and NA. Correlations between mucosal IgA and serum IgG against specific antigens were
33 low, whether before or after challenge, suggesting a compartmentalization of immune responses.
34 Even so, volunteers who developed viral shedding for multiple days had lower baseline titers
35 across both systemic and mucosal compartments as compared to those with no shedding or a
36 single day of shedding. Regression analysis showed that pre-challenge HA inhibition titers were
37 the most consistent correlate of protection across clinical outcomes combining shedding and
38 symptoms, with NA inhibition titers and HA IgG levels only predicting the duration of shedding.
39 Despite the inclusion of data from multiple binding and functional antibody assays against HA
40 and NA performed on both serum and nasal samples, multivariate models were unable to account
41 for the variability in outcomes, emphasizing our imperfect understanding of immune correlates
42 in influenza and the importance of refining models with assessments of innate and cellular
43 immune responses.

44

45

46

47 **Importance:**

48 The devastating potential of influenza has been well known for over 100 years. Despite the
49 development of vaccines since the middle of the twentieth century, influenza continues to be
50 responsible for substantial global morbidity and mortality. To develop next-generation vaccines
51 with enhanced effectiveness, we must synthesize our understanding of the complex immune
52 mechanisms culminating in protection. Our study outlines the differences in immune responses
53 to influenza vaccine and influenza infection, identifying potential gaps in vaccine-induced
54 immunity, particularly at the level of the nasal mucosa. Furthermore, this research underscores
55 the need to refine our imperfect models while recognizing potential pitfalls in past and future
56 attempts to identify and measure correlates of protection.

57

58 **Introduction**

59 Induction of robust, durable immune protection against RNA respiratory viruses such as
60 influenza poses a significant scientific and public health challenge (1). Vaccination is a
61 fundamental component of public health responses, yet the efficacy of current vaccine strategies
62 is limited by viral immune evasion adaptations and waning host immunity. Contemporary
63 vaccines are unable to effectively prevent spread of the virus and often offer inadequate
64 protection to individuals at the highest risk of complications and death. The development of new
65 vaccine strategies offering more robust, broad, and durable protection is urgently needed, but
66 requires an improvement in our understanding of immunoprotection.

67 Existing influenza vaccines induce a systemic immune response to the major surface
68 protein, hemagglutinin (HA), and are standardized by stimulation of serum anti-HA antibodies as
69 the primary correlate of protection. The FDA and EMA CHMP both define “protective titers” as
70 a serum HAI titer of ≥ 40 (2). Despite this acceptance of HA-specific antibodies as a surrogate
71 for immunity, there is a body of research highlighting the importance of the immune response to
72 other antigenic targets, such as neuraminidase (NA) (3-7). The role of mucosal immunity in
73 influenza A virus infection has long been studied (8), and recent research on mucosal immunity
74 against both influenza and SARS-COV-2 has illustrated the significance of nasal IgA in
75 protection against respiratory viruses (9-12). Stimulation of robust mucosal immunity has shown
76 promise as a mechanism to reduce viral transmission, an outcome that is largely unaffected by
77 systemically administered vaccines (13-15). Further potential benefits of strategies targeting
78 mucosal immunity include more potent viral neutralization via polymeric secretory IgA (16, 17)
79 and improved durability of responses (18). Intranasally delivered live-attenuated influenza
80 vaccine has demonstrated a capacity to provide superior efficacy compared to intramuscular

81 vaccine, though inconsistently (19, 20). Hence, the ideal amount, kinetics, and antigenic
82 specificity of mucosal antibodies needed to confer protection from influenza remain unknown.

83 In the setting of this public health and scientific impetus, this trial was designed to
84 investigate mucosal and systemic immunity after influenza vaccination and infection in a human
85 challenge study. This initial report summarizes the immune responses to vaccination and
86 infection, describes the relationship between mucosal and systemic immunity, explores the
87 correlation of immune responses to clinical outcomes, and raises questions that must be
88 addressed as we pursue more protective vaccines against respiratory viruses.

89

90 **Results**

91 **Study Population**

92 The study enrolled a total of 80 participants, 40 who were vaccinated intramuscularly
93 (IM) with standard quadrivalent influenza vaccine (IIV) and 40 who remained unvaccinated.
94 Three participants in the vaccinated cohort withdrew prior to viral challenge, 2 due to voluntary
95 withdrawal and 1 due to safety lab abnormalities. Three in the unvaccinated cohort withdrew
96 prior to viral challenge; 2 voluntarily withdrew, and 1 had a positive nasal wash for another
97 respiratory virus prior to challenge. Therefore, 74 participants (37 per cohort) were challenged
98 with influenza and included in the final analysis. The average age of participants was 34 years.
99 Similar distributions of age, race, gender, and ethnicity were enrolled in both the vaccinated and
100 unvaccinated cohorts (Table 1).

101

102 **Clinical Outcomes**

103 The binary clinical outcomes of the viral challenge are summarized in Table 2. Compared
104 to the unvaccinated cohort, a significantly lower proportion of the vaccinated cohort developed
105 Flu (defined as at least one symptom, plus either at least one day of viral shedding or a ≥ 4 -fold
106 increase in either HAI or NAI titers), mild to moderate influenza disease (MMID, defined as at
107 least one symptom plus at least one day of viral shedding), and symptoms. While shedding was
108 less common in vaccinated participants, this difference was not statistically significant. In the
109 vaccinated vs. unvaccinated cohort, trends towards shorter duration of shedding, shorter duration
110 of symptoms, and lower number of symptoms were observed ($p=0.0944$, $p=0.0819$, and
111 $p=0.0634$, respectively) (Figure 1, Table S2). InFLUenza Patient-Reported Outcome (FLU-
112 PRO©) scores, a validated measure of symptom severity, were lower in the vaccinated cohort
113 ($p=0.0434$) (Figure 1, Table S2) (21).

114

115 **Serum and Nasal Humoral Immune Responses**

116 Antibody titers from serum and nasal mucosa were assessed pre- and post-challenge in
117 both cohorts, and in the vaccinated cohort, pre- and post-vaccination. Twenty-eight days after
118 vaccination, significant increases in serum anti-HA IgG and anti-HA stalk IgG ELISA titers
119 (Figure 4) were observed ($p<0.0001$ for both), as well as a modest increase in serum HAI titers
120 that was not statistically significant (Figure 2). However, no increase was observed in serum
121 antibodies against NA, or in mucosal IgA titers against HA, HA stalk or NA (Figure 2, 3, 4).

122 The vaccinated cohort demonstrated rises in HA inhibition (22) titers between day -1 pre-
123 challenge and day 56 post-challenge ($p=0.0011$), despite starting with a significantly higher HAI
124 titer than the unvaccinated cohort on day -1 ($p<0.0001$) (Figure 2). HAI titers also increased by
125 day 56 post-challenge, compared to day -1 pre-challenge, in the unvaccinated cohort ($p<0.0001$)

126 (Figure 2), with more individuals developing a ≥ 4 -fold rise in titer than in the vaccinated cohort
127 (29 vs. 15, $p=0.0001$) (Table S2). However, we observed an overall higher HAI titer in the
128 vaccinated cohort on day 56 than in the unvaccinated ($p=0.0416$) (Figure 2). There was also an
129 increase in NAI titers on day 56 post-challenge compared to day -1 pre-challenge in both the
130 unvaccinated cohort ($p=0.0114$) and the vaccinated cohort ($p=0.0701$), though the latter did not
131 reach statistical significance. No difference in mean NA inhibition (NAI) titer was noted between
132 the cohorts on day 56 (Figure 3).

133 Prior to challenge, vaccinated participants had higher anti-HA IgG and anti-HA stalk
134 serum IgG ($p<0.0001$ for both) compared to unvaccinated participants. There were no between-
135 group differences in the other day -1 serum or any of the mucosal antibody titers from the
136 vaccinated and unvaccinated cohorts (Figure 2, Figure 3, Figure 4). In the vaccinated cohort,
137 there was an increase in mucosal anti-HA IgA and anti-NA IgA on day 7 ($p<0.0001$, 0.0004 ,
138 respectively) and mucosal anti-HA IgA on day 28 ($p=0.027$) after challenge. In unvaccinated
139 individuals, we observed similar rises in mucosal anti-HA IgA and anti-NA IgA titers by day 7
140 ($p<0.0001$, <0.0001 , respectively), and we observed the rise in anti-HA IgA to be sustained
141 longer, at both day 28 ($p=0.0002$) and day 56 ($p=0.0007$) (Figure 2, Figure 3). Overall, on day 56
142 post-challenge, the vaccinated cohort demonstrated higher levels of anti-HA IgG and anti-Stalk
143 IgG in the serum ($p<0.0001$, <0.0001 , respectively) compared to the unvaccinated. No other
144 serum or mucosal ELISA titers were significantly different between study cohorts on day 56
145 post-challenge. When comparing the change in titer levels from day -1 pre-challenge to other
146 study timepoints between vaccinated and unvaccinated cohorts, only the change from day -1 pre-
147 challenge to day 56 post challenge in serum anti-NA IgG was significantly different ($p=0.0032$),

148 with unvaccinated subjects having a larger increase compared to vaccinated (Figure 2, Figure 3,
149 Figure 4, Table S3).

150

151 **Correlations between Serum and Nasal Humoral Immune Responses**

152 For all participants regardless of vaccination cohort, the correlations between antibody
153 titers were generated at multiple timepoints (pre-challenge, 7 days post-challenge, and 56 days
154 post-challenge), and the correlations were generally similar across timepoints except where
155 noted. Serum HAI titers were highly correlated to serum HA IgG and, to a lesser degree, HA
156 stalk IgG, but not NA IgG (Figure 5). Serum NAI titers were moderately correlated to serum NA
157 IgG titers (significantly at day -1 and day 7 but not day 56), but not to serum HA IgG or HA
158 stalk IgG. Serum HA IgG correlated well with serum HA stalk IgG pre-challenge, and serum NA
159 IgG generally did not correlate well with HA IgG (except at day 56, ρ 0.411) or HA stalk IgG.
160 Nasal HA IgA, HA stalk IgA, and NA IgA correlated moderately well with each other. Notably,
161 serum IgG titers against each antigen had no correlation with nasal IgA titers against the same
162 antigen (e.g., serum HA IgG and nasal HA IgA). None of the antigen-specific antibody titers
163 demonstrated correlation with total serum IgG or IgA levels. Serum antibody titers against
164 specific antigens had high correlations across timepoints (e.g., HA IgG at day -1 compared to
165 HA IgG at day 7) and were highly statistically significant (Table S4). In contrast, mucosal
166 antibody responses across timepoints correlated less strongly (Table S4).

167

168 **Comparisons of Clinical Outcomes and Humoral Responses by Shedding Status**

169 Grouping participants by duration of shedding (non-shedders, 1-day shedders, long-
170 shedders) demonstrated significant differences in multiple antibody titers across groups, with the

171 highest titers seen in non-shedders and 1-day shedders and the lowest in long-shedders, for
172 serum HAI, serum NAI, serum HA IgG, and nasal HA IgA. Antibody titers were not
173 significantly different between non-shedders and 1-day shedders (Table 3, Table S5). The
174 proportion of symptoms and number of symptoms were different across groups, but pairwise
175 differences were not statistically significant when adjusted for multiple comparisons (Table 4).

176

177 **Correlates of Protection Assessment through Regression Modelling**

178 In all participants combined, pre-challenge serum HAI titers were observed to have a
179 significant, independent, negative association with Flu, MMID, shedding, and days of shedding
180 (Table S6, Table S7). Serum NAI titers and HA IgG at day -1 were also independently
181 negatively associated with days of shedding. When vaccination cohorts were evaluated
182 separately, only HAI titer and serum anti-HA IgG at day -1 were significantly negatively
183 associated with days of shedding in vaccinated participants. In the unvaccinated cohort, none of
184 the studied immune measures demonstrated an ability to predict outcome measures (Table S8,
185 Table S9).

186 Multivariate models were identified using the Akaike information criterion (AIC), but all
187 of them had R^2 values of ≤ 0.5 , with the majority < 0.1 (Table S10). The best models with the
188 largest R^2 in each cohort related to shedding and days of shedding; of note, the models for the
189 vaccinated cohort were more complex than those for the unvaccinated but had higher R^2 values,
190 indicating slightly better performance as predictive models.

191

192 **Discussion**

193 The ability of IIV to prevent influenza in this study was modest, resulting in only a 33%

194 difference in proportions of Flu incidence between groups. This estimate fits well with real-
195 world measures of effectiveness, validating the challenge model as a vaccine assessment tool
196 (23, 24). In our study, vaccination did not confer a significant reduction in incidence of shedding,
197 suggesting that the ability of IIV to prevent transmission may be very limited. This shortcoming
198 may exist because the vaccine, given via the IM route, provoked no measurable induction of
199 mucosal humoral immunity, as has been observed previously with IM influenza vaccines (25-
200 33). Additionally, our observation that IM vaccination failed to increase antibody titers against
201 NA is unsurprising, considering that the NA content of IIV is low and not standardized (34).

202 Immunity induced by IM vaccination contrasted profoundly with that induced by
203 influenza infection, which provoked significant mucosal antibody titers against HA and NA by
204 day 7. Mucosal responses appeared short-lived, peaking 7 days after challenge, in contrast to
205 serum HAI and NAI titers, which peaked at day 56 (despite stable or decreasing levels of serum
206 HA IgG and NA IgG after day 7). The discordance between the kinetics of functional and
207 binding antibody titers in serum may reflect the effect of affinity maturation. Interestingly,
208 participants in both cohorts experienced increases in serum titers after challenge, suggesting
209 exposure to influenza may be important in boosting vaccine-induced systemic immunity.
210 Unvaccinated individuals narrowed the difference in HAI titers by day 56, but never fully closed
211 the gap with vaccinated individuals. The differential timing of the peak in mucosal IgA (early in
212 the course of infection) versus serum HAI and serum NAI titers (in the recovery phase) may
213 reflect differing immunologic roles of these antibodies, with IgA assisting in viral clearance and
214 serum HAI and NAI contributing to long-term protection against future infections. In contrast,
215 serum and mucosal antibody titers against HA stalk were not affected by challenge but did
216 increase significantly after vaccination. While the general lack of HA stalk-directed humoral

217 response has been primarily blamed on the immunodominance of the head domain (35), the
218 discordance in responses to virus and IIV seen in this study supports the hypothesis that steric
219 hinderance in intact virions contributes to diminished stalk responses (36). Furthermore, IIV
220 demonstrated some potential as an HA-stalk vaccine, considering its ability to boost antibodies
221 against stalk. Strategies to develop HA-stalk specific vaccines should include direct comparisons
222 to currently approved IIV, to ensure elicited responses are superior.

223 The relationships between antibody titers measured in this study provide additional
224 understanding of immune responses against influenza and may help guide next-generation
225 vaccine design. Interestingly, there was no correlation between mucosal IgA titers and serum
226 IgG titers against specific antigens. Similar findings have been recently reported in research on
227 COVID-19 and may reflect differences between populations of IgA-producing plasma cells
228 (residing locally in the mucosal lamina propria) and IgG-producing plasma cells (residing at
229 distant sites such as bone marrow) (10, 15, 37, 38). Systemic antibody titers may, therefore, not
230 be an appropriate surrogate for mucosal antibodies. The consistent lack of correlation across
231 post-challenge timepoints further strengthens these conclusions. These findings also suggest that
232 a vaccination strategy targeting the respiratory mucosa could be used to complement
233 systemically administered vaccine, thereby boosting titers in both compartments.

234 Strong correlations were observed among systemic titers across multiple timepoints
235 within individuals, meaning that participants with lower titers, despite experiencing a boost with
236 challenge, continued to have relatively lower titers after challenge. Mucosal antibody levels lack
237 this within-subject consistency over time. Further research is necessary to determine if titer
238 differences between individuals are due to host factors, or if they reflect differences in
239 immunologic history, such as the number, timing, and intensity of influenza exposures.

240 *Post-hoc* analysis of participants grouped by duration of shedding (0, 1, or >1 days)
241 revealed significant differences in pre-challenge antibody titers, thereby providing a glimpse into
242 potential correlates of protection. As expected, non-shedders had the highest antibody titers and
243 long-shedders had the lowest titers, with differences noted between serum HAI, NAI, HA IgG,
244 and nasal HA IgA, suggesting these are important markers of protection. Notably, 1-day
245 shedders had baseline antibody titers more like non-shedders, rather than long-term shedders.

246 More sophisticated, direct analysis performed through regression modelling identified a
247 few significant associations, with HAI titers at day -1 predicting outcomes related to shedding,
248 duration of shedding, MMID, and Flu. Notably, we did not observe an association between
249 mucosal antibody titers and clinical outcomes, in contrast to findings from a previous influenza
250 challenge study (12). In addition, NAI titers were not as crucially predictive of clinical outcomes
251 as was observed in aggregate data of four previous challenge studies conducted by our group (4).
252 However, in almost all of these previous studies, participants were required to have low baseline
253 serum HAI titers pre-challenge, which likely decreased the impact of HAI titers and increased
254 the relative contribution of other correlates of protection, like serum NAI and mucosal IgA. In
255 contrast, the administration of IM vaccine in this study boosted the contribution of HAI titers to
256 protection and consequently decreased the signal from other immune correlates (39).

257 In a similar study performed in 1986 by Clements, *et al.*, participants were given
258 intranasal (IN) live attenuated influenza vaccination (LAIV) or IM IIV and then challenged with
259 influenza A virus. In the IN LAIV cohort, pre-challenge nasal IgA against HA (as well as serum
260 NAI) correlated with reductions in viral shedding and clinical illness, while in the IIV cohort,
261 only serum-related markers (pre-challenge serum HAI, serum NAI and nasal HA IgG [which
262 results from serum HA IgG spillover]) correlated with these outcomes (40). In our study, IM

263 vaccination predominantly increased serum HAI titers, which emerged as the main correlate of
264 protection. When performing regression analyses separately in the vaccinated and unvaccinated
265 cohorts, HAI titers remained significantly predictive only for duration of shedding in the
266 vaccinated cohort and were not predictive of any outcomes in the unvaccinated cohort. Upon
267 further analysis with multivariate models evaluated using AIC, we found that the models were
268 extremely limited with no R^2 value better than 0.5 and most < 0.1 . Therefore, even after
269 developing models with data representing multi-antigen humoral responses in both serum and
270 mucosa, we were unable to accurately predict most of the variation in outcomes due to influenza
271 infection.

272 There are several limitations to this study. In particular, the small sample size limited our
273 power to detect small differences. The study was not blinded, which may have introduced bias
274 into the reporting of symptoms. In addition, enrollment was not randomized, instead following a
275 pragmatic sequential enrollment approach; selection bias may have contributed to differences in
276 baseline titers between the vaccinated and unvaccinated cohorts. It is important to note that most
277 participants enrolled into the unvaccinated cohort were found to have low (<40) baseline HAI
278 titers. In contrast, the vaccinated cohort had much higher baseline HAI titers, even before
279 vaccination, suggesting potential differences in exposure to influenza or vaccination history.
280 While the study showed short-lived mucosal responses, functional antibody assays were not
281 performed on mucosal samples for comparison to functional antibody assays on serum; thus, the
282 evaluation of mucosal antibodies may be considered less robust. Measurements of cellular
283 immunity and cytokine levels were not available at this time, but these evaluations will be
284 conducted in the future and may further refine our models. Furthermore, additional approaches
285 such as repertoire sequencing, transcriptomics, and machine learning strategies may advance our

286 understanding of the correlates of protection against influenza and guide next-generation vaccine
287 development.

288

289 **Conclusion**

290 The initial results from this study demonstrate that the correlates of protection to
291 influenza are complex and reach beyond systemic or even mucosal antibody titers. These
292 measures, though useful, can only predict clinical outcomes to a limited degree and do not
293 account for the multiple immunological mechanisms underlying protection. For decades our
294 influenza vaccination strategy has targeted the systemic humoral response, namely HAI titers;
295 however, it is clear from this and other studies that we must expand our investigations to
296 encompass the interaction between mucosal and systemic immunity and explore how vaccination
297 in one immune compartment could beneficially or detrimentally effect the other. Further analysis
298 of samples from studies like this will be required to elucidate how the immune system
299 orchestrates cellular, innate, and humoral responses, within both the systemic and mucosal
300 compartments, to combat infection and how we can translate this knowledge into better
301 protection against disease.

302

303 **Materials and Methods**

304 **Study Design**

305 The challenge study was performed at the NIH Clinical Center between April and
306 October of 2019 after participants signed consent. The primary objective was to identify mucosal
307 correlates of protection against influenza in vaccinated and unvaccinated healthy volunteers.
308 Protection was evaluated using a primary endpoint of Flu defined as at least one symptom of

309 influenza plus either 1) a positive clinical test for influenza within 10 days of inoculation or 2) a
310 fourfold or greater increase in anti-HA or anti-NA antibody titer at 56 days after administration
311 of challenge virus. Secondary protection endpoints included incidence of shedding, incidence of
312 symptoms, duration of shedding, duration and number of symptoms, FLU-PRO score, and
313 incidence of MMID, defined as viral shedding detected by clinical molecular testing plus a
314 minimum of one symptom of influenza after intranasal challenge, as previously described (41).
315 This study (clinicaltrials.gov identifier NCT01971255) was approved by the NIAID Institutional
316 Review Board and was conducted in accordance with the provisions of the Declaration of
317 Helsinki and Good Clinical Practice guidelines.

318 The first 40 participants were enrolled in the vaccinated cohort and were vaccinated IM
319 with IIV (Flucelvax®), referred to as phase 1 of the study. Mucosal cell samples were collected
320 from the middle turbinate using a nasal speculum and pathology brush. Nasal secretion samples
321 were collected using a synthetic absorbent material (SAM) strip. Mucosal samples, whole blood,
322 PBMCs, and serum were collected pre-vaccination on the day of vaccination as well as on day 3
323 and day 28 post-vaccination. All vaccinations in this cohort were administered 32-155 days prior
324 to challenge (median 64 days). Another 40 participants were identified and enrolled in the
325 unvaccinated cohort, and 74 participants from both cohorts were brought into the NIH Clinical
326 Center as mixed cohorts for challenge with influenza A virus.

327 All participants were challenged with 10^7 TCID₅₀ of the Influenza
328 A/Bethesda/MM2/H1N1 challenge virus and were assessed daily for a minimum of 9 days in the
329 isolation unit as previously described, referred to as phase 2 of the study (41). Mucosal and
330 systemic samples were collected pre-challenge (the day prior to inoculation) and on days 1, 3, 5,

331 and 7 post-challenge. Samples were also collected on day 28 and day 56 post-challenge during
332 outpatient follow-up.

333

334 **Vaccine**

335

336 The licensed 2018-2019 northern hemisphere version of Flucelvax® Quadrivalent,

337 produced by Seqirus (Holly Springs, North Carolina), was administered to the vaccinated cohort.

338 It contained 15 micrograms of each of 4 virus HA subunits including H3N2, H1N1, and two

339 Influenza B.

340

341 **Sample Collection and Processing**

342 Whole blood and serum were collected and processed. Nasal brushings were placed in

343 RNA Later and stored at -80°C prior to extraction for further analysis. Nasal SAM strips were

344 frozen initially at -80°C and then were thawed on ice for processing. The absorbent strip was

345 removed from its handle and placed into a micro centrifuge tube. Elution buffer (300 µl, 1%

346 BSA in PBS) was added on top of the SAM strip. The tube containing the strip with buffer was

347 vortexed for 30 seconds. Using sterile forceps, the strip was removed, a spin filter mini-column

348 (catalog no. 9301; Costar) was inserted in the same tube, and the strip was replaced inside

349 column. Samples were centrifuged at 16,000 x g for 20 min at 4°C. After removing samples from

350 the centrifuge, the strip and spin column were removed. The eluate was aliquoted and stored at -

351 80°C.

352

353 **Immunologic Assays**

354 Standard methods were used to measure serum HAI and NAI antibody titers against the
355 challenge virus (42-44). ELISA for IgA and IgG antibodies against HA, NA, and HA stalk was
356 performed on nasal secretions and serum, respectively, as previously described (45, 46) with
357 minor modifications (Table S1).

358

359 **Calculation of IgA and IgG antibody titers against HA, NA, and HA stalk**

360 Antibody titers were calculated using an extrapolation method. Four serum and SAM
361 samples with the highest reactivity to each construct (HA, NA, and HA stalk) were preselected
362 using the ELISA technique described. These samples were pooled in equal volumes and serially
363 diluted to create the standard for its respective construct and sample type. This standard was used
364 to generate a standard curve against the determined titer for each plate. The titer was determined
365 by running an ELISA plate per antigen with the standard serially diluted multiple times, with
366 various dilution factors. The OD₄₉₀ of each dilution was measured using the ELISA method
367 described, and the cutoff value was set as the mean optical density (OD) plus 3 standard
368 deviations (47) of the wells containing only the secondary antibody. The titer was defined as the
369 highest dilution factor to produce an OD value above the generated cutoff value. The titer of the
370 mucosal sample standard was 37,500 for HA, 8,600 for NA, and 16,000 for HA stalk. The titer
371 of the serum standard was 409,600 for HA, 12,800 for NA, and 218,000 for HA stalk. Serial
372 dilutions of the standard were added to each plate to generate the standard curve. The constructs'
373 antibody titers were measured three times independently and means of the replicates were used
374 for further analysis.

375

376 **Statistical Analysis**

377 Participants were divided among two groups: vaccinated and unvaccinated. Wilcoxon
378 rank sum tests were used to compare continuous outcomes between groups and within a group
379 between timepoints. Fisher's exact tests were used for categorical outcomes. Univariate linear
380 regression models were used to examine the relationship between log-transformed antibody titer
381 values and continuous outcomes of number of symptoms, number of days of symptoms, number
382 of days of shedding, and FLU-PRO scores for each group separately, and for all subjects
383 combined. Univariate logistic regression models were used to examine the relationship between
384 log-transformed antibody titer values and binary outcomes of presence of Flu, symptoms,
385 shedding, and MMID for each group separately and for all subjects combined. Spearman's rank
386 correlations coefficients were calculated for specified sets of antibody titers at days -1, 7, and 56.
387 Spearman's rank correlations coefficients were also calculated for all antibody titers between
388 timepoints (days -1 and 7, days -1 and 56, days 7 and 56). Participants were grouped by shedding
389 duration into three groups: non-shedders, 1-day shedders, and long-shedders (>1 day of
390 shedding). Kruskal-Wallis tests were used to compare pre-challenge antibody titers and post-
391 challenge symptom-based clinical outcomes between the shedding groups. An exhaustive search
392 to find the best model fit using AIC was done using all log-transformed antibody measures at
393 phase 2 day -1 as predictors for each outcome measure. The model with the lowest AIC was
394 selected and the R^2 was calculated. Groups were modeled separately. P-values were adjusted for
395 multiple comparisons to maintain the 0.05 level of significance as detailed in the supplementary
396 appendix. All analyses were done in R version 3.6.3. Heatmap figures were created in Prism
397 9.3.1.

398

399 **Acknowledgments:**

400 This project has been funded in in part with federal funds from the National Cancer Institute,
401 National Institutes of Health, under Contract No. 75N91019D00024 and in part with funding
402 from the Division of Intramural Research, NIAID. The content of this publication does not
403 necessarily reflect the views or policies of the Department of Health and Human Services, nor
404 does mention of trade names, commercial products, or organizations imply endorsement by the
405 U.S. Government.

406

407

408

409 .

410

411

412 **References:**

- 413
- 414 1. Morens DM, Taubenberger JK, Fauci AS. 2023. Rethinking next-generation vaccines for
415 coronaviruses, influenzaviruses, and other respiratory viruses. *Cell Host Microbe* 31:146-
416 157.
- 417 2. Cox R. 2013. Correlates of protection to influenza virus, where do we go from here?
418 *Human Vaccines & Immunotherapeutics* 9:405-408.
- 419 3. Memoli MJ, Shaw PA, Han A, Czajkowski L, Reed S, Athota R, Bristol T, Fargis S, Risos K,
420 Powers JH, Davey RT, Taubenberger JK. 2016. Evaluation of Antihemagglutinin and
421 Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus
422 Healthy Human Challenge Model. *mBio* 7.
- 423 4. Giurgea LT, Cervantes-Medina A, Walters KA, Scherler K, Han A, Czajkowski LM, Baus HA,
424 Hunsberger S, Klein SL, Kash JC, Taubenberger JK, Memoli MJ. 2022. Sex Differences in
425 Influenza: The Challenge Study Experience. *J Infect Dis* 225:715-722.
- 426 5. Maier HE, Nachbagauer R, Kuan G, Ng S, Lopez R, Sanchez N, Stadlbauer D, Gresh L,
427 Schiller A, Rajabhathor A, Ojeda S, Guglia AF, Amanat F, Balmaseda A, Krammer F,
428 Gordon A. 2020. Pre-existing Antineuraminidase Antibodies Are Associated With
429 Shortened Duration of Influenza A(H1N1)pdm Virus Shedding and Illness in Naturally
430 Infected Adults. *Clin Infect Dis* 70:2290-2297.
- 431 6. Monto A, Kendal A. 1973. Effect of neuraminidase antibody on Hong Kong influenza. *The*
432 *Lancet* 301:623-625.
- 433 7. Monto AS, Petrie JG, Cross RT, Johnson E, Liu M, Zhong W, Levine M, Katz JM, Ohmit SE.
434 2015. Antibody to Influenza Virus Neuraminidase: An Independent Correlate of
435 Protection. *Journal of Infectious Diseases* 212:1191-1199.
- 436 8. Shvartsman YS, Zykov MP. 1976. Secretory anti-influenza immunity. *Adv Immunol*
437 22:291-330.
- 438 9. Sheikh-Mohamed S, Isho B, Chao GYC, Zuo M, Cohen C, Lustig Y, Nahass GR, Salomon-
439 Shulman RE, Blacker G, Fazel-Zarandi M, Rathod B, Colwill K, Jamal A, Li Z, de Launay KQ,
440 Takaoka A, Garnham-Takaoka J, Patel A, Fahim C, Paterson A, Li AX, Haq N, Barati S,
441 Gilbert L, Green K, Mozafarihashjin M, Samaan P, Budyłowski P, Siqueira WL, Mubareka
442 S, Ostrowski M, Rini JM, Rojas OL, Weissman IL, Tal MC, McGeer A, Regev-Yochay G,
443 Straus S, Gingras AC, Gommerman JL. 2022. Systemic and mucosal IgA responses are
444 variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with
445 protection against subsequent infection. *Mucosal Immunol* 15:799-808.
- 446 10. Havervall S, Marking U, Svensson J, Greilert-Norin N, Bacchus P, Nilsson P, Hober S,
447 Gordon M, Blom K, Klingstrom J, Aberg M, Smed-Sorensen A, Thalín C. 2022. Anti-Spike
448 Mucosal IgA Protection against SARS-CoV-2 Omicron Infection. *N Engl J Med* 387:1333-
449 1336.
- 450 11. Zuo F, Marcotte H, Hammarstrom L, Pan-Hammarstrom Q. 2022. Mucosal IgA against
451 SARS-CoV-2 Omicron Infection. *N Engl J Med* 387:e55.
- 452 12. Gould VMW, Francis JN, Anderson KJ, Georges B, Cope AV, Tregoning JS. 2017. Nasal IgA
453 Provides Protection against Human Influenza Challenge in Volunteers with Low Serum
454 Influenza Antibody Titre. *Frontiers in Microbiology* 8.

- 455 13. McMahon M, Kirkpatrick E, Stadlbauer D, Strohmeier S, Bouvier NM, Krammer F. 2019.
456 Mucosal Immunity against Neuraminidase Prevents Influenza B Virus Transmission in
457 Guinea Pigs. *mBio* 10.
- 458 14. Mao T, Israelow B, Pena-Hernandez MA, Suberi A, Zhou L, Luyten S, Reschke M, Dong H,
459 Homer RJ, Saltzman WM, Iwasaki A. 2022. Unadjuvanted intranasal spike vaccine elicits
460 protective mucosal immunity against sarbecoviruses. *Science* 378:eabo2523.
- 461 15. Focosi D, Maggi F, Casadevall A. 2022. Mucosal Vaccines, Sterilizing Immunity, and the
462 Future of SARS-CoV-2 Virulence. *Viruses* 14.
- 463 16. Aina A, Tamura S-i, Suzuki T, Ito R, Asanuma H, Tanimoto T, Gomi Y, Manabe S, Ishikawa
464 T, Okuno Y, Odagiri T, Tashiro M, Sata T, Kurata T, Hasegawa H. 2011. Characterization
465 of neutralizing antibodies in adults after intranasal vaccination with an inactivated
466 influenza vaccine. *Journal of Medical Virology* 84:336-344.
- 467 17. Suzuki T, Kawaguchi A, Aina A, Tamura S-i, Ito R, Multihartina P, Setiawaty V, Pangesti
468 KNA, Odagiri T, Tashiro M, Hasegawa H. 2015. Relationship of the quaternary structure
469 of human secretory IgA to neutralization of influenza virus. *Proceedings of the National
470 Academy of Sciences* 112:7809-7814.
- 471 18. Treanor J, Nolan C, O'Brien D, Burt D, Lowell G, Linden J, Fries L. 2006. Intranasal
472 administration of a proteosome-influenza vaccine is well-tolerated and induces serum
473 and nasal secretion influenza antibodies in healthy human subjects. *Vaccine* 24:254-262.
- 474 19. Ashkenazi S, Vertruyen A, Aristegui J, Esposito S, McKeith DD, Klemola T, Biolek J, Kuhr J,
475 Bujnowski T, Desgrandchamps D, Cheng SM, Skinner J, Gruber WC, Forrest BD, Group C-
476 TS. 2006. Superior relative efficacy of live attenuated influenza vaccine compared with
477 inactivated influenza vaccine in young children with recurrent respiratory tract
478 infections. *Pediatr Infect Dis J* 25:870-9.
- 479 20. Chung JR, Flannery B, Thompson MG, Gaglani M, Jackson ML, Monto AS, Nowalk MP,
480 Talbot HK, Treanor JJ, Belongia EA, Murthy K, Jackson LA, Petrie JG, Zimmerman RK,
481 Griffin MR, McLean HQ, Fry AM. 2016. Seasonal Effectiveness of Live Attenuated and
482 Inactivated Influenza Vaccine. *Pediatrics* 137:e20153279.
- 483 21. Han A, Poon JL, Powers JH, 3rd, Leidy NK, Yu R, Memoli MJ. 2018. Using the Influenza
484 Patient-reported Outcome (FLU-PRO) diary to evaluate symptoms of influenza viral
485 infection in a healthy human challenge model. *BMC Infect Dis* 18:353.
- 486 22. Wang TT, Sewatanon J, Memoli MJ, Wrammert J, Bournazos S, Bhaumik SK, Pinsky BA,
487 Chokephaibulkit K, Onlamoon N, Pattanapanyasat K, Taubenberger JK, Ahmed R,
488 Ravetch JV. 2017. IgG antibodies to dengue enhanced for FcγRIIIA binding
489 determine disease severity. *Science* 355:395-398.
- 490 23. 2022. Centers for Disease Control and Prevention. Past Seasons Vaccine Effectiveness
491 Estimates. <https://www.cdc.gov/flu/vaccines-work/effectiveness-studies.htm>. Accessed
492 June 1 2023.
- 493 24. Rondy M, El Omeiri N, Thompson MG, Leveque A, Moren A, Sullivan SG. 2017.
494 Effectiveness of influenza vaccines in preventing severe influenza illness among adults: A
495 systematic review and meta-analysis of test-negative design case-control studies. *J
496 Infect* 75:381-394.

- 497 25. Atmar RL, Keitel WA, Cate TR, Munoz FM, Ruben F, Couch RB. 2007. A dose–response
498 evaluation of inactivated influenza vaccine given intranasally and intramuscularly to
499 healthy young adults. *Vaccine* 25:5367-5373.
- 500 26. Fulk RV, Fedson DS, Huber MA, Fitzpatrick JR, Howar BF, Kasel JA. 1969. Antibody
501 responses in children and elderly persons following local or parenteral administration of
502 an inactivated influenza virus vaccine, A2-Hong Kong-68 variant. *J Immunol* 102:1102-5.
- 503 27. Greenbaum E, Engelhard D, Levy R, Schlezinger M, Morag A, Zakay-Rones Z. 2004.
504 Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following
505 intranasal administration of one or two doses of inactivated, trivalent anti-influenza
506 vaccine. *Vaccine* 22:2566-77.
- 507 28. Kasel JA, Hume EB, Fulk RV, Togo Y, Huber M, Hornick RB. 1969. Antibody responses in
508 nasal secretions and serum of elderly persons following local or parenteral
509 administration of inactivated influenza virus vaccine. *J Immunol* 102:555-62.
- 510 29. Keitel WA, Cate TR, Nino D, Huggins LL, Six HR, Quarles JM, Couch RB. 2001.
511 Immunization against influenza: comparison of various topical and parenteral regimens
512 containing inactivated and/or live attenuated vaccines in healthy adults. *J Infect Dis*
513 183:329-332.
- 514 30. Muhamed G, Greenbaum E, Zakay-Rones Z. 2006. Neuraminidase antibody response to
515 inactivated influenza virus vaccine following intranasal and intramuscular vaccination.
516 *Isr Med Assoc J* 8:155-8.
- 517 31. Muszkat M, Greenbaum E, Ben-Yehuda A, Oster M, Yeu'l E, Heimann S, Levy R, Friedman
518 G, Zakay-Rones Z. 2003. Local and systemic immune response in nursing-home elderly
519 following intranasal or intramuscular immunization with inactivated influenza vaccine.
520 *Vaccine* 21:1180-6.
- 521 32. Waldman RH, Kasel JA, Fulk RV, Togo Y, Hornick RB, Heiner GG, Dawkins AT, Mann JJ.
522 1968. Influenza Antibody in Human Respiratory Secretions after Subcutaneous or
523 Respiratory Immunization with Inactivated Virus. *Nature* 218:594-595.
- 524 33. Zahradnik JM, Kasel JA, Martin RR, Six HR, Cate TR. 1983. Immune responses in serum
525 and respiratory secretions following vaccination with a live cold-recombinant (CR35) and
526 inactivated A/USSR/77 (H1N1) influenza virus vaccine. *J Med Virol* 11:277-85.
- 527 34. Giurgea LT, Morens DM, Taubenberger JK, Memoli MJ. 2020. Influenza Neuraminidase:
528 A Neglected Protein and Its Potential for a Better Influenza Vaccine. *Vaccines (Basel)* 8.
- 529 35. Zost SJ, Wu NC, Hensley SE, Wilson IA. 2019. Immunodominance and Antigenic Variation
530 of Influenza Virus Hemagglutinin: Implications for Design of Universal Vaccine
531 Immunogens. *J Infect Dis* 219:S38-S45.
- 532 36. Tan HX, Jegaskanda S, Juno JA, Esterbauer R, Wong J, Kelly HG, Liu Y, Tilmanis D, Hurt
533 AC, Yewdell JW, Kent SJ, Wheatley AK. 2019. Subdominance and poor intrinsic
534 immunogenicity limit humoral immunity targeting influenza HA stem. *J Clin Invest*
535 129:850-862.
- 536 37. Cohen JI, Dropulic L, Wang K, Gangler K, Morgan K, Liepshutz K, Krogmann T, Ali MA, Qin
537 J, Wang J, Vogel JS, Lei Y, Suzuki-Williams LP, Spalding C, Palmore TN, Burbelo PD. 2023.
538 Comparison of Levels of Nasal, Salivary, and Plasma Antibody to Severe Acute
539 Respiratory Syndrome Coronavirus 2 During Natural Infection and After Vaccination. *Clin*
540 *Infect Dis* 76:1391-1399.

- 541 38. Wright PF, Prevost-Reilly AC, Natarajan H, Brickley EB, Connor RI, Wieland-Alter WF,
542 Miele AS, Weiner JA, Nerenz RD, Ackerman ME. 2022. Longitudinal Systemic and
543 Mucosal Immune Responses to SARS-CoV-2 Infection. *J Infect Dis* 226:1204-1214.
- 544 39. Johansson BE, Moran TM, Kilbourne ED. 1987. Antigen-presenting B cells and helper T
545 cells cooperatively mediate intravirion antigenic competition between influenza A
546 virus surface glycoproteins. *Proc Natl Acad Sci U S A* 84:6869-73.
- 547 40. Clements ML, Betts RF, Tierney EL, Murphy BR. 1986. Serum and nasal wash antibodies
548 associated with resistance to experimental challenge with influenza A wild-type virus. *J*
549 *Clin Microbiol* 24:157-60.
- 550 41. Memoli MJ, Czajkowski L, Reed S, Athota R, Bristol T, Proudfoot K, Fargis S, Stein M,
551 Dunfee RL, Shaw PA, Davey RT, Taubenberger JK. 2015. Validation of the wild-type
552 influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding
553 investigational new drug study. *Clin Infect Dis* 60:693-702.
- 554 42. Cottey R, Rowe CA, Bender BS. 2001. Influenza virus. *Curr Protoc Immunol* Chapter
555 19:Unit 19.11.
- 556 43. Potter CW, Oxford JS. 1979. Determinants of immunity to influenza infection in man. *Br*
557 *Med Bull* 35:69-75.
- 558 44. Wan H, Gao J, Xu K, Chen H, Couzens LK, Rivers KH, Easterbrook JD, Yang K, Zhong L,
559 Rajabi M, Ye J, Sultana I, Wan XF, Liu X, Perez DR, Taubenberger JK, Eichelberger MC.
560 2013. Molecular basis for broad neuraminidase immunity: conserved epitopes in
561 seasonal and pandemic H1N1 as well as H5N1 influenza viruses. *J Virol* 87:9290-300.
- 562 45. Park JK, Xiao Y, Ramuta MD, Rosas LA, Fong S, Matthews AM, Freeman AD, Gouzoulis
563 MA, Batchenkova NA, Yang X, Scherler K, Qi L, Reed S, Athota R, Czajkowski L, Han A,
564 Morens DM, Walters KA, Memoli MJ, Kash JC, Taubenberger JK. 2020. Pre-existing
565 immunity to influenza virus hemagglutinin stalk might drive selection for antibody-
566 escape mutant viruses in a human challenge model. *Nat Med* 26:1240-1246.
- 567 46. Park JK, Han A, Czajkowski L, Reed S, Athota R, Bristol T, Rosas LA, Cervantes-Medina A,
568 Taubenberger JK, Memoli MJ. 2018. Evaluation of Preexisting Anti-Hemagglutinin Stalk
569 Antibody as a Correlate of Protection in a Healthy Volunteer Challenge with Influenza
570 A/H1N1pdm Virus. *mBio* 9.
- 571 47. Layne SP, Beugelsdijk TJ, Patel CK, Taubenberger JK, Cox NJ, Gust ID, Hay AJ, Tashiro M,
572 Lavanchy D. 2001. A global lab against influenza. *Science* 293:1729.
- 573
574

575 **Figure Legends:**

576

577 Fig 1

578 Clinical outcomes after challenge demonstrating duration (days) of shedding (A), duration (days)
579 of symptoms (B), total number of symptoms (C), and FLU-PRO (D) scores, which standardize
580 symptom severity based on number of symptoms and duration with higher numbers signifying
581 more severe illness. Individual values represented by dots for unvaccinated participants in blue
582 and vaccinated participants in yellow. Horizontal lines represent medians and first and third
583 quartiles. P-values from Wilcoxon rank sum tests comparing unvaccinated and vaccinated
584 participants shown, with $p < 0.05$ considered statistically significant.

585

586 Fig 2

587 Antibody titers after vaccination (Phase 1) and H1N1 viral challenge (Phase 2) as tested by
588 hemagglutinin (HA) inhibition (22) assays (A), ELISA for nasal anti-HA IgA (B), and ELISA
589 for serum anti-HA IgG (C). In phase 1, day 0 represents baseline titers on the day of vaccination.
590 Subsequently in phase 2, day -1 represents baseline titers prior to viral challenge on day 0.
591 Individual values represented by dots for unvaccinated participants in blue and vaccinated
592 participants in yellow. Horizontal lines represent medians and first and third quartiles. Vertical
593 lines represent minimum and maximum non-outliers. P-values from Wilcoxon rank sum tests,
594 adjusted for multiple comparisons by Holm's method, comparing unvaccinated and vaccinated
595 participants shown, with $p < 0.05$ considered statistically significant. Important non-significant
596 (N.S.) comparisons also shown.

597

598 Fig 3

599 Antibody titers after vaccination (Phase 1) and H1N1 viral challenge (Phase 2) as tested by
600 neuraminidase (NA) inhibition (NAI) assays (A), ELISA for nasal anti-NA IgA (B), and ELISA
601 for serum anti-NA IgG (C). In phase 1, day 0 represents baseline titers on the day of vaccination.
602 Subsequently in phase 2, day -1 represents baseline titers prior to viral challenge on day 0.
603 Individual values represented by dots for unvaccinated participants in blue and vaccinated
604 participants in yellow. Horizontal lines represent medians and first and third quartiles. Vertical
605 lines represent minimum and maximum non-outliers. P-values from Wilcoxon rank sum tests,
606 adjusted for multiple comparisons by Holm's method, comparing unvaccinated and vaccinated
607 participants shown, with $p < 0.05$ considered statistically significant. Important non-significant
608 (N.S.) comparisons also shown.

609

610 Fig 4

611 Antibody titers after vaccination (Phase 1) and H1N1 viral challenge (Phase 2) as tested by
612 ELISA for nasal anti-HA stalk IgA (A) and ELISA for serum anti-HA stalk IgG (B). In phase 1,
613 day 0 represents baseline titers on the day of vaccination. Subsequently in phase 2, day -1
614 represents baseline titers prior to viral challenge on day 0. Individual values represented by dots
615 for unvaccinated participants in blue and vaccinated participants in yellow. Horizontal lines
616 represent medians and first and third quartiles. Vertical lines represent minimum and maximum
617 non-outliers. P-values from Wilcoxon rank sum tests, adjusted for multiple comparisons by
618 Holm's method, comparing unvaccinated and vaccinated participants shown, with $p < 0.05$
619 considered statistically significant. Important non-significant (N.S.) comparisons also shown.

620

621 Fig 5
622 Heatmaps of spearman rank correlation coefficients between serum and nasal antibody titers.
623 Numbers within squares and square colors represent rho values, with blue indicating positive and
624 red representing negative correlations. Green asterisks indicate statistically significant
625 comparisons after Bonferroni adjustment. Black squares represent comparisons left untested for
626 scientific or statistical reasons.

627 **Tables:**

628 Table 1. Demographics of Participants

629

	Overall	Unvaccinated	Vaccinated
Total N	74	37	37
Race			
White	38 (51.4%)	20 (54.1%)	18 (48.6%)
Black	27 (36.5%)	12 (32.4%)	15 (40.5%)
Asian	2 (2.7%)	0 (0.0%)	2 (5.4%)
Multiple Race	5 (6.8%)	4 (10.8%)	1 (2.7%)
Unknown	2 (2.7%)	1 (2.7%)	1 (2.7%)
Ethnicity			
Hispanic or Latino	11 (14.9%)	4 (10.8%)	7 (18.9%)
Not Hispanic or Latino	61 (82.4%)	31 (83.8%)	30 (81.1%)
Unknown	2 (2.7%)	2 (5.4%)	0 (0.0%)
Gender			
Female	40 (54.1%)	20 (54.1%)	20 (54.1%)
Male	34 (45.9%)	17 (45.9%)	17 (45.9%)
Enrollment Age	34 (8.20)	34 (8.86)	34 (7.61)

Categorical variables are presented as N (%) and continuous variables are presented as mean (SD).

630

631

632

633

634

Table 2. Incidence of Binary Clinical Outcomes after H1N1 Challenge

	Unvaccinated N (%)	Vaccinated N (%)	P-Value ^a
Total N	37	37	
MMID ^b	30 (81%)	18 (49%)	0.0068
Flu ^c	34 (92%)	22 (59%)	0.0023
Symptoms ^d	35 (95%)	27 (73%)	0.0242
Shedding ^e	30 (81%)	23 (62%)	0.1208

^aP-values from Fisher's Exact Tests with no adjustment for multiple comparisons

^bMMID (mild to moderate influenza disease) defined as at least 1 influenza symptom plus at least 1 day of viral shedding

^cFlu defined as at least 1 influenza symptom, plus either at least 1 day of viral shedding or a ≥ 4 fold increase in either hemagglutinin inhibition titers or neuraminidase inhibition titers

^dSymptoms defined as presence of at least 1 influenza symptom

^eShedding defined as presence of shedding on at least 1 day

635

636

637

638

639

640

641

642

643

644

Table 3. Median Antibody Titers before H1N1 Challenge at Day -1 Grouped by Participant Shedding Status

	Non-shedders	1-day shedders	Long-shedders ^a	P-Value ^b
Total N	21	19	34	
Serum HAI	80	80	20	0.0008
Serum NAI	160	160	80	0.0079
Serum HA IgG	447088	402805	290263	0.0008
Serum HA Stalk IgG	187087	196786	130218	0.0739
Serum NA	5967	4556	3879	0.1633
Nasal HA IgA	953	790	467	0.0273
Nasal HA Stalk IgA	586	1215	790	0.2374
Nasal NA IgA	36	35	35	0.8814

645 ^aLong-shedders defined as those with 2 or more days of shedding
 646 ^bP-values from Kruskal-Wallis tests (pairwise Wilcoxon rank sum tests adjusted by the Benjamini-Hochberg method
 647 performed when p-value <0.05, results available in supplemental)
 648 ^cSymptoms defined as presence of at least 1 influenza symptom
 649 ^dShedding defined as presence of shedding on at least 1 day
 650 HAI – hemagglutinin inhibition, NAI – neuraminidase inhibition, HA – hemagglutinin, NA – neuraminidase
 651

652 Table 4. Clinical Outcomes after H1N1 Challenge Grouped by Participant Shedding Status
 653

	Non-shedders	1-day shedders	Long-shedders ^a	P-Value ^b
Total N	21	19	34	
Shedding ^{c,d}	0	19 (100%)	34 (100%)	
Symptoms ^d	14 (67%)	18 (95%)	30 (88%)	0.0350
MMID ^{c,e}	0	18 (95%)	30 (88%)	
Flu ^{c,f}	8 (38%)	18 (95%)	30 (88%)	
Median (IQR) Days of Shedding ^c	0 (0, 0)	1 (1, 1)	3 (2, 4)	
Median (IQR) Days of Symptoms	3 (0, 5)	5 (3, 6.5)	4 (2, 6.75)	0.1363
Median (IQR) Number of symptoms	2 (0, 4)	4 (2.5, 6.5)	3 (2, 5)	0.0268

654 ^aLong-shedders defined as those with 2 or more days of shedding
 655 ^bP-values from Kruskal-Wallis tests (pairwise Wilcoxon rank sum tests adjusted by the Benjamini-Hochberg method
 656 performed when p-value <0.05, results available in supplemental)
 657 ^cStatistical analysis not performed on shedding outcomes between groups, which are defined by shedding status, and
 658 outcomes that are dependent on shedding status (Flu, MMID)
 659 ^dSymptoms defined as presence of at least 1 influenza symptom
 660 ^eShedding defined as presence of shedding on at least 1 day
 661 ^fMMID (mild to moderate influenza disease) defined as at least 1 influenza symptom plus at least 1 day of viral
 662 shedding
 663 ^fFlu defined as at least 1 influenza symptom, plus either at least 1 day of viral shedding or a ≥ 4 fold increase in
 664 either hemagglutinin inhibition titers or neuraminidase inhibition titers
 665 IQR – interquartile range
 666




Fig 1 Clinical outcomes after challenge demonstrating duration (days) of shedding (A), duration (days) of symptoms (B), total number of symptoms (C), and FLU-PRO (D) scores, which standardize symptom severity based on number of symptoms and duration with higher numbers signifying more severe illness. Individual values represented by dots for unvaccinated participants in blue and vaccinated participants in yellow. Horizontal lines represent medians and first and third quartiles. P-values from Wilcoxon rank sum tests comparing unvaccinated and vaccinated participants shown, with $p < 0.05$ considered statistically significant.




Fig 2 Antibody titers after vaccination (Phase 1) and H1N1 viral challenge (Phase 2) as tested by hemagglutinin (HA) inhibition (HAI) assays (A), ELISA for nasal anti-HA IgA (B), and ELISA for serum anti-HA IgG (C). In phase 1, day 0 represents baseline titers on the day of vaccination. Subsequently in phase 2, day -1 represents baseline titers prior to viral challenge on day 0. Individual values represented by dots for unvaccinated participants in blue and vaccinated participants in yellow. Horizontal lines represent medians and first and third quartiles. Vertical lines represent minimum and maximum non-outliers. P-values from Wilcoxon rank sum tests, adjusted for multiple comparisons by Holm's method, comparing unvaccinated and vaccinated participants shown, with $p < 0.05$ considered statistically significant. Important non-significant (N.S.) comparisons also shown.




Fig 3 Antibody titers after vaccination (Phase 1) and H1N1 viral challenge (Phase 2) as tested by neuraminidase (NA) inhibition (NAI) assays (A), ELISA for nasal anti-NA IgA (B), and ELISA for serum anti-NA IgG (C). In phase 1, day 0 represents baseline titers on the day of vaccination. Subsequently in phase 2, day -1 represents baseline titers prior to viral challenge on day 0. Individual values represented by dots for unvaccinated participants in blue and vaccinated participants in yellow. Horizontal lines represent medians and first and third quartiles. Vertical lines represent minimum and maximum non-outliers. P-values from Wilcoxon rank sum tests, adjusted for multiple comparisons by Holm's method, comparing unvaccinated and vaccinated participants shown, with $p < 0.05$ considered statistically significant. Important non-significant (N.S.) comparisons also shown.




Fig 4 Antibody titers after vaccination (Phase 1) and H1N1 viral challenge (Phase 2) as tested by ELISA for nasal anti-HA stalk IgA (A) and ELISA for serum anti-HA stalk IgG (B). In phase 1, day 0 represents baseline titers on the day of vaccination. Subsequently in phase 2, day -1 represents baseline titers prior to viral challenge on day 0. Individual values represented by dots for unvaccinated participants in blue and vaccinated participants in yellow. Horizontal lines represent medians and first and third quartiles. Vertical lines represent minimum and maximum non-outliers. P-values from Wilcoxon rank sum tests, adjusted for multiple comparisons by Holm's method, comparing unvaccinated and vaccinated participants shown, with $p < 0.05$ considered statistically significant. Important non-significant (N.S.) comparisons also shown.

